Eli Lilly (LLY) Payables (2009 - 2026)

Eli Lilly has reported Payables for 18 years, with the latest figure at $5.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 46.11% year-over-year to $5.0 billion; the trailing twelve-month figure through Mar 2026 stood at $5.0 billion (up 46.11% YoY), and the FY2025 full-year result was $5.4 billion, up 17.57% from the prior year.
• Payables for Q1 2026 stood at $5.0 billion, down from $5.4 billion in the prior quarter.
• The five-year high for Payables was $5.4 billion in Q2 2025, with the low at $1.4 billion in Q1 2022.
• Historically, Payables has averaged $3.4 billion across 5 years, with a median of $3.4 billion in 2025.
• Annual changes were most pronounced in 2022 — Payables fell 12.58% — and 2025, when it soared 47.66%.
• Eli Lilly's Payables stood at $2.9 billion in 2022, then advanced by 27.82% to $3.8 billion in 2023, then gained by 21.43% to $4.6 billion in 2024, then grew by 17.57% to $5.4 billion in 2025, then dropped by 6.51% to $5.0 billion in 2026.
• The last three Payables figures came in at $5.0 billion (Q1 2026), $5.4 billion (Q4 2025), and $4.3 billion (Q3 2025), per Business Quant data.